PubMed Health⌕ Search

Biomedical subjects

R Hamazoe

Publications and source records attributed to R Hamazoe.

At least 55 records · Page 3Linked to original sources
PubMed1985

Immunosuppressive factor from the spleen in gastric cancer patients.

The spleens of gastric cancer patients were examined to determine whether this organ releases an immunosuppressive factor. Compared to serum from peripheral blood, serum from splenic venous blood of advanced gastric cancer patients had greater suppressive activity to normal lymphocyte responses to phytohemagglutinin (PHA); it also contained significantly more immune complexes. Furthermore, the supernatant from spleen cell cultures from advanced gastric cancer patients significantly suppressed normal lymphocyte responses to PHA. This immunosuppressive activity was enhanced when the supernatant was from cultures of separated nonadherent subpopulations. These observations were not detected in patients with early gastric cancer. The blastogenic response to PHA and the percentage of T-cells among spleen cells was not affected by the cancer stage. These results suggest that the spleen of patients with advanced gastric cancer participates in the induction of serum immunosuppressive factors, possibly due to a change in splenic lymphocyte subsets.

Antigen-Antibody Complex↗
PubMed1985

Clinical effects of total-body hyperthermia combined with anticancer chemotherapy for far-advanced gastrointestinal cancer.

The authors treated 17 patients with far-advanced gastrointestinal cancer with extracorporeally induced total-body hyperthermia (TBHT) combined with anticancer chemotherapy. Although all patients' tumors were clinically resistant to prior chemotherapy with 1-(2-tetrahydrofurlyl)-5-fluorouracil or 5-fluorouracil and mitomycin C, three patients had an objective response to TBHT plus the same anticancer agents with or without cyclophosphamide. That is, a partial response was obtained in 2 of 12 patients with recurrent gastric cancer and in 1 of 5 patients with recurrent large bowel cancer. However, their survival time was not markedly prolonged. As a characteristic complication of TBHT, the authors noted reversible weakness of the muscles of the lower extremities. Two patients died due to hepatorenal syndrome; preoperatively these patients had manifested hepatic or renal dysfunction. Therefore, in patients with hepatic or renal dysfunction, the application of TBHT must be considered carefully.

Adult↗
PubMed1985

Congenital choledochal dilatation associated with carcinoma after choledochocystoduodenostomy--case report and a review of the literature.

A 24-year old Japanese woman with congenital choledochal dilatation associated with carcinoma, cholelithiasis and pancreatolithiasis was treated. She had undergone choledochocystoduodenostomy at the age of 5 years. At the present admission, a dilated choledochus was excised and hepaticojejunostomy (Roux-en-Y anastomosis) and pancreatic ductojejunostomy were performed. Adenocarcinoma involved the entire mucosal surface of the resected specimen. We also present a review of the literature on the treatment and prognosis of patients with congenital biliary dilatation associated with carcinoma after bypass operation in childhood. We emphasize that in patients with congenital choledochal dilatation, the dilated choledochus should be excised, even in young children.

Adult↗
PubMed1985

[Clinical significance of the determination of serum carbohydrate antigen 19-9 in patients with carcinoma of the stomach and colorectum].

Serum CA 19-9 levels were measured in 68 gastric cancer patients and 38 cases of colorectal cancer. In patients with stage I-III gastric cancer or Duckes A-C colorectal cancer, the CA 19-9 levels ranged from normal to 127 U/ml, whereas in more advanced cases it was very high. Classified by the mode of recurrence, the highest level of CA 19-9 was observed in liver metastasis. After removal of the main tumor, the CA 19-9 level declined rapidly, increasing with recurrence. Serum CA 19-9 determination in cases of gastric or colorectal cancer was useful to classify the stage of disease, developing a prognosis and identifying a recurrence.

Antigens, Neoplasm↗
PubMed1984

Circulating immune complexes in gastric cancer patients and their effect on lymphocyte mitogenesis (the first report).

Immune complexes (IC) were measured in 66 gastric cancer patients, using the 3.5 percent polyethylene glycol (PEG) precipitation method. Preoperatively, the IC values in patients with advanced gastric cancer (stages III and IV) were significantly higher than in normal subjects (p less than 0.01). In the presence of 3.5 percent PEG-precipitated IC from sera of gastric cancer patients, the mitogen responses of normal peripheral blood lymphocytes was inhibited; the PHA response revealed a significant negative correlation with the concentration of IC (p less than 0.01). Our data suggest that IC may be a major serum factor exerting immunosuppressive effect in cancer hosts.

Antigen-Antibody Complex↗
PubMed1984

Effect of extracorporeally induced total body hyperthermia for cancer on cardiovascular function.

Total body hyperthermia (TBHT) was induced in patients with terminal cancer, using a femoral arterio-venous shunt as an extracorporeal circuit incorporating a heat exchanger. A total of 31 systemic hyperthermic treatments lasting 3 to 4 hours at 41.5 degrees C to 42 degrees C (rectal temperature) were performed on 11 patients; chemotherapy had previously been unsuccessful in all of these cases. The effect of TBHT on cardiovascular function was explored in these patients. The heart rate and cardiac output were always markedly increased during hyperthermia, however, the peripheral arterial, central venous, pulmonary arterial and pulmonary wedge pressures were little affected and no progressive metabolic acidosis occurred. TBHT was generally well tolerated and there was no instance in which this treatment had to be terminated because of severe cardiovascular failure during hyperthermia.

Adult↗
PubMed1984

[Serum levels of mitomycin C following a high-dose continuous hyperthermic peritoneal perfusion].

Valid therapeutic means have not been established for treatment of disseminated peritoneal metastasis of carcinoma. Continuous hyperthermic peritoneal perfusion (CHPP) with high-dose of mitomycin-C (MMC) was applied to 26 patients with peritoneal metastasis from gastric, rectal or ovarian cancers. Levels of MMC in the sera and in the perfusate were measured. The results obtained were: 1. Approximately a half of the dose of MMC added into the perfusion fluid was recovered. 2. When perfused with 100 mg of MMC, the maximum serum concentration of MMC was equivalent to 1/3 of the maximum serum level when injected with 10 mg of MMC intravenously. Therefore, MMC which could not be detected in CHPP seemed to be retained in the abdominal cavity. 3. Bone marrow inhibition caused by CHPP was observed in only 2 of 26 patients. 4. The total dose of 300 mg of MMC, consisting of the maximum dose of 100 mg each, is acceptable in CHPP without any severe side effect. 5. CHPP exerts antitumor effects when utilizing hyperthermia and a high-dose of MMC on the disseminated peritoneal foci of carcinoma.

Female↗
PubMed1984

Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug.

To study the feasibility of combined hyperthermic and anticancer drug treatment for peritoneal cancer, we devised a continuous hyperthermic peritoneal perfusion system in combination with mitomycin C. The model uses i.p.-transplantable rat ascites hepatoma 100B cells. Hyperthermic peritoneal perfusion alone or combined with mitomycin C was performed after i.p. inoculation of the tumor cells into rats. In rats treated with combined peritoneal perfusion (41.5 degrees) and mitomycin C, the mean survival times were significantly prolonged as compared to those of rats treated with peritoneal perfusion at 41.5 degrees alone. Our results suggest that combined hyperthermic peritoneal perfusion and mitomycin C treatment may represent a therapeutic and prophylactic treatment for peritoneal metastasis after gastric cancer surgery in humans.

Animals↗
PubMed1983

Immunosuppressive acidic protein (IAP) in gastric cancer patients.

Immunosuppressive acidic protein (IAP) in the serum from peripheral, splenic and regional venous blood of gastric cancer patients was assayed. Peripheral venous blood was collected before, and for several months after the surgery. The IAP values of peripheral venous blood, increased with advancing cancer stage; in patients at the same cancer stage, the IAP values of venous blood draining from the cancer lesion were the highest. In curatively operated patients, the IAP values increased during the first postoperative month and decreased thereafter. In patients with non-resectable cancer and in patients subjected to palliative surgery, these values remained high; they increased sharply just before death. Determination of the serum IAP values in gastric cancer patients may be useful in estimating the immunological state of gastric cancer patients and for monitoring the postoperative immunological status.

Gastrectomy↗
PubMed1983

[Application of heat combined with antineoplastic agent administration in the treatment of cancer (with special reference to malignancy of the digestive system)].

Recently, there is a renewed interest in the efficacy of hyperthermia in human cancer therapy. Based on the results of our experimental studies, we treated far-advanced cancer patients with extracorporeally induced total-body hyperthermia (TBHT) or continuous hyperthermic peritoneal perfusion (CHPP). In the TBHT combined with anticancer chemotherapy, a partial remission was observed in 4 (25.0%) of 16 far-advanced cancer patients. However, the improvement of survival time was unsatisfactory. The CHPP combined with anticancer chemotherapy was performed in 23 gastric cancer patients with peritoneal dissemination. In 6 of them, subjective complaints were improved, but the remarkable prolongation of survival time was not obtained. If in the future hyperthermochemotherapy is performed for cancer recurrence in early stage, more favourable results may be expected.

Adult↗
PubMed1983

[Short-term intensive chemotherapy (STIC) combined with intravenous hyperalimentation in advanced stomach cancer].

A short-term intensive chemotherapy (STIC) consisting of large dose of mitomycin C (MMC), tegafur (FT-207), streptococcus preparation picibanil (OK-432) and Krestin (PSK), combined with IVH was performed in 72 patients with advanced gastric cancer. Thirty-three patients were unresectable and 39 patients were recurrent. In this modality, an intensive chemotherapy was able to carry out, maintaining, or increasing in host immunologic parameters and body weight in spite of their disturbed condition in oral food take. Partial response was obtained in 10 of 51 evaluable cases (19.6%) and the survival period on STIC was superior to that on controls. However, no significant difference was observed between the two groups. Four patients had become to be able to take full oral food again by STIC and resulted in the removal of IVH. Hyperglycemia and septicaemia induced by IVH were observed in 9 of 72 patients (12.5%), one died of septicaemia. Full attention should be paid in the management of IVH for patients with advanced cancer.

Adult↗
PubMed1983

[Experimental studies on continuous hyperthermic peritoneal perfusion in the treatment for peritoneal metastases of cancer].

As a preliminary study to apply thermotherapy or thermochemotherapy to the treatment of peritoneal dissemination of gastric cancer, a continuous hyperthermic peritoneal perfusion (CHPP) was carried out for the experimental peritoneal dissemination of Donryu rats inoculated with AH100B ascitic hepatoma cells (AH100B cells). Firstly, the cytotoxicity of heat on AH100B cells was studied. No cytotoxicity was observed at 37 degrees C, but mild cytotoxicity was noted at 41.5 degrees C, and marked rise in cytotoxicity was seen at 42.5 degrees C. These cytotoxicity increased with addition to Mitomycin C and prolongation of the heating time. Next, on the 1st, 5th and 10th day after inoculation of AH100B cells, the Donryu rats were treated as follows: Group 1; CHPP (37 degrees C for 1 hr), Group 2; CHPP (41.5 degrees C for 1 hr), Group 3; (42.5 degrees C for 1 hr), Group 4; CHPP (41.5 degrees C for 1 hr)+MMC 1 mg/kg (intraperitoneal administration immediately after completion of CHPP). Group 5; MMC 1 mg/kg (intraperitoneal administration). Death within 48 hours after perfusion occurred in one rat of the 41.5 degrees C perfusion group and 14 rats of the 42.5 degrees C perfusion group. Comparison of the survival time on these groups showed the most remarkable life-prolonging effect in CHPP (41.5 degrees C)+MMC group. On the basis of the results of this study, the CHPP method combined with anti-cancer chemotherapy is considered to be an useful treatment for peritoneal dissemination of cancer.

Animals↗
PubMed1983

[Immunological significance of splenectomy in gastric cancer surgery. Production of immunosuppressive factor in the spleen].

We studied immunological significance of splenectomy in gastric cancer surgery with special reference to serum suppressor factor. The results showed that the sera from splenic venous blood in advanced gastric cancer was more suppressive to PHA blastogenesis of normal lymphocytes and also higher in the values of circulating immune complexes, as compared to the sera from peripheral blood. Furthermore, the media from cultures of spleen cells of patients with advanced gastric cancer indicated to suppress PHA blastogenesis of normal lymphocytes, as compared to the media from cultures of peripheral lymphocytes of the same patients. The suppressive activity was more increased in the media from cultures of nonadherent cell population obtained from the spleen cells. From these data, it was suggested that the spleen of patients with advanced gastric cancer was capable of producing serum suppressor factor. Therefore, gastrectomy combined with splenectomy may be reasonable in patients with advanced gastric cancer.

Antigen-Antibody Complex↗
PubMed1982

Effect of regional or distant lymph node removal and of splenectomy on immunologic responses in Ehrlich tumor-bearing mice.

To study the role of regional (RLN) and distant (DLN) lymph nodes and of the spleen in the regulation of tumor immunity, we monitored tumor growth in mice subjected to lymph node removal or splenectomy. We found that tumor growth was facilitated when RLN were removed before or soon after tumor inoculation and that RLN removal after extirpation of the immunizing tumor decreased the host resistance to a subsequent challenge. When splenectomy preceded tumor inoculation, tumor growth was not affected, however, marked growth inhibition was observed when splenectomy was performed 5 days after tumor inoculation. Furthermore, splenectomy combined with extirpation of the immunizing tumor increased the host resistance to a subsequent challenge. We conclude from these studies that RLN or the spleen may be of immunologic importance in the host's tumor resistance.

Animals↗